ObjectiveTo evaluate the survival results of surgical resection (SR) and CT-guided percutaneous ablation (PA) for stageⅠnon-small cell lung cancer (NSCLC).MethodsThe PubMed, Web of Science, EMbase, The Cochrane Library, CNKI, VIP, Wanfang databases from inception to June 2021 were searched to collect comparative studies on the survival results between SR and CT-guided PA treatment for stageⅠNSCLC. RevMan 5.3 software was used for statistical analysis of data.ResultsA total of 3 114 patients were included in 11 studies. The results of meta-analysis showed that compared with the PA group, the SR group had a higher 2-year postoperative overall survival (OS) rate (OR=1.44, 95%CI 1.00-2.06, P=0.05), 3-year postoperative OS rate (OR=2.37, 95%CI 1.47-3.81, P<0.001), 5-year OS rate (OR=1.64, 95%CI 1.19-2.28, P<0.01), 5-year progression-free survival rate after operation (OR=2.43, 95%CI 1.54-3.82, P<0.001) and lower local recurrence rate (OR=0.26, 95%CI 0.13-0.54, P<0.001). There were no statistical differences between the two groups in terms of 1-year postoperative OS rate, 1-year, 2-year, and 3-year tumor-related survival rates, 1-year, 2-year tumor-free survival rates, or distant postoperative recurrence rate (P>0.05).ConclusionFor patients with stageⅠNSCLC with optimal basic conditions, surgery is a more appropriate treatment. For patients who cannot withstand surgical injuries or refuse surgery, CT-guided PA is also a potential alternative treatment. However, this conclusion needs to be verified by prospective controlled trials with larger sample sizes and a more rigorous design.
[Abstract]High-grade histologic subtypes of lung adenocarcinoma, such as micropapillary and solid patterns, are characterized by high invasiveness, increased risk of recurrence, and poor prognosis. Early preoperative identification of these subtypes is crucial for achieving individualized treatment and improving clinical outcomes. This review summarizes the clinical features, imaging manifestations, molecular mechanisms, and diagnostic advances related to these aggressive patterns. Studies have shown that micropapillary and solid subtypes are more common in male smokers, often present as solid nodules, and demonstrate strong predictive value in FDG-PET metabolic parameters and CT-based radiomics models. At the molecular level, EGFR mutations are more frequently observed in micropapillary types, whereas solid subtypes are often associated with high PD-L1 expression and TP53 mutations, indicating distinct therapeutic strategies for targeted and immunotherapies. In addition, serum markers such as CEA and CYFRA21-1, along with inflammatory indices like NLR and SII, may serve as auxiliary tools for subtype identification. Histologic subtypes of lung adenocarcinoma are evolving from descriptive classifications into critical determinants of treatment decisions and precision management. Clinicians should incorporate comprehensive histologic evaluation into individualized therapeutic planning. Multimodal integration technologies, combined with artificial intelligence algorithms, are advancing the accurate preoperative prediction and management of high-risk subtypes, thereby facilitating early diagnosis and stratified treatment of lung adenocarcinoma.